TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 31 Mar 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Nalotimagene-carmaleucel (Primary) ; Cyclophosphamide; Ganciclovir; T cell replacement therapy; Valganciclovir
Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Registrational; Therapeutic Use
Sponsors AGC Biologics; MolMed

31 Mar 2022 This trial has been completed in Croatia, as per European Clinical Trials Database record.
01 Jun 2021 Status changed from recruiting to discontinued.
21 Nov 2020 This trial has been discontinued in Italy, as per European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com